RT Journal Article
SR Electronic
T1 Sequencing identifies multiple, early introductions of SARS-CoV2 to New York City Region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20064931
DO 10.1101/2020.04.15.20064931
A1 Matthew T. Maurano
A1 Sitharam Ramaswami
A1 Gael Westby
A1 Paul Zappile
A1 Dacia Dimartino
A1 Guomiao Shen
A1 Xiaojun Feng
A1 André M. Ribeiro-dos-Santos
A1 Nicholas A. Vulpescu
A1 Margaret Black
A1 Megan S. Hogan
A1 Christian Marier
A1 Peter Meyn
A1 Yutong Zhang
A1 John Cadley
A1 Raquel Ordoñez
A1 Raven Luther
A1 Emily Huang
A1 Emily Guzman
A1 Antonio Serrano
A1 Brendan Belovarac
A1 Tatyana Gindin
A1 Andrew Lytle
A1 Jared Pinnell
A1 Theodore Vougiouklakis
A1 Ludovic Boytard
A1 John Chen
A1 Lawrence H. Lin
A1 Amy Rapkiewicz
A1 Vanessa Raabe
A1 Marie I. Samanovic-Golden
A1 George Jour
A1 Iman Osman
A1 Maria Aguero-Rosenfeld
A1 Mark J. Mulligan
A1 Paolo Cotzia
A1 Matija Snuderl
A1 Adriana Heguy
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.15.20064931.abstract
AB Effective public response to a pandemic relies upon accurate measurement of the extent and dynamics of an outbreak. Viral genome sequencing has emerged as a powerful approach to link seemingly unrelated cases, and large-scale sequencing surveillance can inform on critical epidemiological parameters. Here, we report the analysis of 236 SARS-CoV2 sequences from cases in the New York City metropolitan area during the initial stages of the 2020 COVID-19 outbreak. The majority of cases throughout the region had no recent travel history or known exposure, and genetically linked cases were spread throughout the region. Comparison to global viral sequences showed that the majority were most related to cases from Europe. Our data are consistent with numerous seed transmissions from multiple sources and a prolonged period of unrecognized community spreading. This work highlights the complementary role of real-time genomic surveillance in addition to traditional epidemiological indicators.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by NIH grants P30CA016087 (NYU Langone Genome Technology Center), UM1AI148574 (M.J.M), and R35GM119703 to (M.T.M.). This work was partially supported by the NYULH Office for Science and Research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences have been deposited into the GISAID repository immediately upon QC and can be visualized at http://nextstrain.org/ncov . http://www.mauranolab.org/SARSCoV2.html